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Abstract: Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on 
treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of 
partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the 
efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients 
are frequently excluded from clinical trials. Here, a comprehensive overview of available data 
regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled 
analysis conducted in patients aged $65 years, no new/unexpected safety findings have emerged. 
Few data from uncontrolled investigations suggest that ZNS may be effective and well toler-
ated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. 
However, evidence from these observational studies is less than satisfactory, and randomized 
controlled trials focused on these patients are still needed.
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Introduction
Epilepsy is one of the most serious disorders of the brain with about 50 million people 
affected worldwide.1 The incidence of epilepsy is highest at the younger and older 
age, and around 30% of new epilepsies arise in older patients. The prevalence rate of 
epilepsy in subjects aged over 70 years is quite twice that in children,2 and the incidence 
rates increase significantly with age for every decade after 60 years of age.1,3 With 
life expectancy becoming progressively longer, especially in high-income countries, 
the prevalence of epilepsy in the elderly should increase and to understand its epide-
miology is a matter of significant public health importance. Evidence on the optimal 
treatment of epilepsy in old age is limited, mainly because older patients are often 
excluded from randomized clinical trials.4 Because of the unfavorable pharmacoki-
netic and safety profile5,6 of first-generation antiepileptic drugs (AEDs) in the elderly, 
there has been an increasing attention on newer pharmacological alternatives for this 
population. However, comparative randomized double-blind studies about the use of 
second-generation AEDs in older subjects with newly diagnosed epilepsy are few,7–9 
and only observational studies have been carried out for some medications.10–12
Zonisamide (ZNS), a second-generation AED, has been recently approved in 
Europe as monotherapy for the treatment of partial seizures in adults with newly 
diagnosed epilepsy. This agent is also approved in Europe and USA as adjunctive 
therapy of focal seizures with or without secondary generalization with a proven 
safety and tolerability profile.13,14 A recent pooled analysis of clinical studies, where 
patients with epilepsy aged $65 years treated with ZNS were enrolled, showed a 
favorable safety/tolerability profile.4 This, in combination with the negligible expected 
drug interactions, and the advantage of once-daily dosing,15 has led to an increasing 
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interest in the potential use of this AED for epilepsy therapy 
in the elderly.
This review provides a comprehensive overview of 
available data on ZNS in the management of elderly people 
with epilepsy.
Literature search strategy
Studies discussed in this paper were searched by using the 
EMBASE and the PubMed databases from inception to 
November 28, 2014. The following keywords were used: 
“zonisamide”, “epilepsy”, and “elderly.”
Further data were also searched from abstracts of 
International Conference Proceedings (Annual Meetings 
of the American Epilepsy Society and the Congresses of 
the International League Against Epilepsy). However, 
abstracts often do not show all relevant details and are not 
as rigorously peer reviewed as journal articles. Finally, 
the references of the selected papers were reviewed for 
additional articles.
Pharmacology: mechanism of action
ZNS has been documented to exhibit multiple mechanisms of 
action. ZNS has been shown to block both sodium and T-type 
Ca2+ channels.15 These mechanisms of action contribute to the 
stabilization of neuronal membranes and to the suppression 
of hypersynchronization.
In addition, ZNS has been reported to affect the gluta-
matergic and γ-aminobutyric acid-ergic neurotransmitter 
systems,16–20 to increase striatal and hippocampal concentra-
tion of dopamine and serotonin (total and extracellular) and 
to alter acetylcholine metabolism. Furthermore, ZNS has 
been demonstrated to weakly inhibit carbonic anhydrase 
activity.16,17 The clinical relevance of these mechanisms to 
antiseizure activity is still unclear.20
Pharmacokinetic profile
After oral administration, ZNS is rapidly absorbed and its oral 
bioavailability is virtually complete. The peak plasma con-
centration (C
max
) ranges between 2.3 mg/mL and 12.5 mg/mL 
(from 200 mg to 800 mg), depending on the dosage, and is 
reached in 2.4–3.6 hours (T
max
). The presence of food does 




ZNS has an apparent volume of distribution of about 
1.1–1.8 L/kg. Plasma ZNS levels increase proportionally for 
doses of 200–400 mg.21,22
ZNS is partially bound to the human serum albumin 
(about 50%) and preferentially accumulated in erythro-
cytes.23 The elimination half-life of ZNS in plasma depends 
on the presence of cytochrome P450 (CYP)3A4 microsomal 
enzyme inducers (ie, phenobarbital, carba mazepine, and 
phenytoin) and ranges from about 50–70 hours in patients 
non-treated with enzyme inducers to 25–35 hours in the 
treated ones.24 This long half-life allows the once-daily 
dosing.17 The apparent oral clearance is 15–20 mL/h/kg in 
patients non-treated concomitantly with enzyme inducers 
and 20–30 mL/h/kg in patients treated with enzyme 
inducers.24
The favorable pharmacokinetic profile supports the 
increasing use of ZNS. No major influences of ZNS on 
the pharmacokinetics of other concomitant medications 
have been reported. In particular, in patients on monother-
apy with carbamazepine,25 valproic acid,26 phenytoin,27 or 
lamotrigine,28 the introduction of ZNS (up to 400 mg/day) 
as add-on treatment did not affect the steady-state serum 
levels. In patients co-medicated with phenobarbital, 
carbamazepine, and phenytoin, the exposure to ZNS is 
decreased and the steady-state plasma levels are reached 
within a week.17
Metabolism and excretion
ZNS, before predominant excretion by renal route, undergoes 
hepatic biotransformation.29
In particular, ZNS is mainly metabolized in the open-ring 
metabolite, 2-sulfamoylacetyl phenol, by the CYP3A4 isoen-
zyme, in the N-acetyl derivative by the N-acetyltransferase, 
and, to a lesser extent, directly conjugated to the glucuronic 
acid. These metabolites are pharmacologically inactive. 
Of the excreted dose, 15%–30% was recovered as unchanged 
drug, 20% as ZNS glucuronide and N-acetyl ZNS, and 50% 
as the 2-sulfamoylacetyl phenol glucuronide.29,30
Pharmacokinetic profile in special 
groups
The influence of aging on the pharmacokinetic profile of 
ZNS was assessed in a study16,31 conducted in healthy vol-
unteers, 11 elderly (65–71 years) compared to 11 young 
(21–40 years), after oral administration of a single dose 
(300 mg). Wallace et al31 found that the elimination half-life 
of ZNS was 51.9 hours in the older subjects and 65.7 hours 
in the younger subjects, probably as a result of the smaller 
volume of distribution in the older population (1.19 L/kg) 
compared with the non-elderly segment (1.44 L/kg). No 
significant differences in renal clearance, mean plasma area 
under the serum concentration-time curve (AUC), and mean 
plasma clearance were found, and dose adjustments were 
not necessary. A single-dose study in subjects with renal 
impairment demonstrated that ZNS clearance was decreased 
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significantly, and a 35% AUC increase was observed in 
subjects with creatinine clearance values ,20 mL/min.16,23
Efficacy
There are limited data available on the efficacy of ZNS in 
the elderly population with focal epilepsy. Only one Phase 
IV randomized controlled trial and few uncontrolled stud-
ies reported data regarding the efficacy of ZNS in elderly 
patients with epilepsy.
Randomized controlled study
Results from a 16-week Phase IV randomized placebo- 
controlled study investigating the safety and tolerability profile 
of ZNS as add-on therapy in elderly patients with refractory 
focal epilepsy concomitantly treated with one or two AEDs32 
(NCT01546688 clinicaltrial.gov/show/NCT01546688) show 
exploratory efficacy data on ZNS. This research has not yet 
been published but only a few data have been made avail-
able by the sponsor. Evidence from the results section of 
clinicaltrial.gov/show/NCT01546688 (last updated June 30, 
2014) indicates that 33 patients (mean age 72.5 years) were 
enrolled in the treatment arm (five not completed study, 
none for lack of efficacy) and 18 (mean age 71.1 years) in 
the placebo arm (three not completed study, one for lack of 
efficacy). Although statistical analysis of efficacy data is not 
provided, the treatment group showed 75% of responders 
compared to 62% of responders in the placebo group during 
the last 28 days of the maintenance period. In addition, the 
median percent change in seizure frequency from baseline 
during the last 28 days of the maintenance period was similar 
in both the groups.
Uncontrolled studies
Data presented at the 25th International Epilepsy Congress 
Proceedings reported in a retrospective open-label study33 
efficacy and safety of ZNS as monotherapy/add-on treat-
ment in patients affected by focal and primary generalized 
epilepsy stratified by age. A large part of the elderly group 
(.60 years) received concomitant antiepileptic treatment, 
and the mean dosage of ZNS was 475 mg/day. Seizure 
freedom was achieved in 27% of elderly patients, while a 
75%–99.9% reduction in seizure frequency was reached in 
27%. The authors did not state the exact number of older 
patients treated.
A further retrospective 8-week open-label study34 investi-
gated 20 elderly patients (range 49–89 years, mean 64.1 years) 
with complex partial seizures treated with ZNS as add-on 
therapy. The ZNS dosage ranged from 100 mg once daily 
to 100 mg bid (twice daily) or 200 mg once daily on the 
basis of clinical response. Three patients were affected by 
post-traumatic epilepsy, four by postanoxic damage, three 
were affected by stroke-related epilepsy, and ten by crypto-
genic epilepsy. Three out of 20 patients (15%) experienced 
seizure freedom, and 16 out of 20 patients (80%) reported 
a reduction .50% in seizure frequency. No dropouts were 
reported in the responder group. Tosches and Tisdell35 
described 53 patients out of 60 patients identified ($60 years, 
mean 76 years, range 60–97) treated with ZNS for $3 months. 
Thirty-seven patients were treated with ZNS as monotherapy 
(mean dose 200 mg/day, mean duration 28.2 months). Twenty 
out of 37 patients (54.1%) obtained seizure freedom, and a 
$50% reduction in seizure frequency was achieved in further 
five patients (13.5%). The “add-on” group (16 patients, mean 
dose 268.8 mg/day, mean duration 35.3 months) showed sei-
zure freedom in five patients (31.2%) and a $50% reduction 
in seizure frequency in an additional seven patients (43.8%). 
The authors also reported positive neurological effects with 
the improvement of extrapyramidal tremor (n=2), improved 
awareness (n=2), mood (n=1), and also postherpetic neuralgia 
(n=1) and restless legs syndrome (n=1). In another retrospec-
tive study36 of 417 old adults from the Columbia AED data-
base comparing effectiveness of ten AEDs, including ZNS 
in older adults (.55 years), 30 patients with epilepsy (mean 
age 64 years) were taking ZNS (median dosage 300 mg/
day). The authors reported a 12-month seizure-freedom rate 
of 22.2% for ZNS (n=18) similar to that obtained for the 
remaining AEDs except for lamotrigine and levetiracetam that 
showed seizure-freedom rates greater than 40% (54.1%, n=85 
and 42.6%, n=68, respectively). The authors also compared 
12-month retention rate (a combined evaluation of efficacy 
and tolerability) in 247 (n=436 subject–drug combinations) 
elderly patients newly treated with any AED over a period 
of 4 years. The highest retention rate was demonstrated for 
lamotrigine (78.6%, n=126), while ZNS, valproate, and leve-
tiracetam showed a 12-month retention rate of 68.2% (n=22), 
69.6% (n=23), and 72.5% (n=102), respectively. The lowest 
retention rate was seen with oxcarbazepine (23.5%, n=34). 
The subgroup evaluation of patients with refractory epilepsy 
(n=250 subject–drug combinations) showed a retention rate of 
90% for valproate (n=10), followed by lamotrigine (77.8%, 
n=63), levetiracetam (71.8, n=85), ZNS (70%, n=20), and 
topiramate (66.7%, n=15).
Safety and tolerability
Pooled analysis of data from clinical 
studies
Recently, a pooled analysis of clinical data (five randomized, 
double-blind and two open-label clinical studies) specifically 





performed to evaluate safety and tolerability profile of ZNS 
in older epileptic patients ($65 years) compared to younger 
patients (18–65 years) has been published.4 In particular, 
Trinka et al analyzed data from 95 elderly patients and 1,389 
younger adult patients and evaluated treatment-emergent 
adverse events (TEAEs). TEAEs were similar in both the 
groups (82% in elderly patients vs 84% in younger adult 
patients). In addition, the incidence of treatment-related 
TEAEs was less in older patients than in younger adults 
(56% vs 73%, respectively). Although these findings may 
be related to different titration schedule and dosages, the 
authors did not report any data regarding titration for both 
the groups. The greater part of TEAEs was mild to moderate 
in each group. Severe TEAEs were reported less frequently 
in elderly subjects compared with the younger group (11.6% 
vs 20.8%). Dizziness (15%), headache (13%), somnolence 
(12%), and fatigue (12%), followed by nasopharyngitis (8%), 
constipation (7%), diarrhea (6%), confusion (6%), pruritus 
(6%), nausea (6%), depression (5%), insomnia (5%), and loss 
of appetite (5%) were the most frequently reported TEAEs in 
the elderly group compared with the younger group. Periph-
eral edema of mild to moderate intensity occurred in 4% of 
elderly subjects vs 1% in the non-elderly adults group.
The main treatment-related TEAEs in elderly patients 
were dizziness (14%), sleepiness (9%), fatigue (8%), and 
pruritus (6%). Only three serious treatment-related TEAEs 
(pancreatitis, rib fracture, and status epilepticus) were 
reported in elderly patients treated with ZNS as add-on 
therapy. One death was considered treatment related due to 
pancreatitis. TEAEs leading to ZNS withdrawal occurring 
in $2% of elderly patients were dizziness (4%), headache 
(2%), sleepiness (2%), and confusion (2%). Trinka et al 
did not report significant changes in the clinical laboratory 
parameters and body weight in the elderly group.4
Randomized controlled study
Recently, a 16-week Phase IV randomized placebo-controlled 
study investigated the safety, tolerability, and efficacy of ZNS 
as adjunctive treatment in elderly patients affected by refrac-
tory focal epilepsy concomitantly treated with one or two 
AEDs (NCT01546688 clinicaltrial.gov/show/NCT01546688, 
last updated June 30, 2014). The clinical data of 33 treated 
patients 18 patients in the placebo arm were reported. Serious 
adverse events were 6/33 (18.2%) with ZNS versus 1/18 
(5.6%) with placebo, whereas other adverse events were 
found in 17 out of 33 (51.5%) elderly patients with epi-
lepsy and in eight out of 18 (44.4%) patients in the placebo 
group. Serious adverse events reported in treated group were 
cardiovascular insufficiency, pancreatitis, sudden death, rib 
fracture, convulsion, status epilepticus, vertebrobasilar insuf-
ficiency, and renal failure (1/33, 3.03% each).
Regarding the other adverse events, the most reported in 
the ZNS group were dizziness (5/33, 15.15% vs 2/18, 11.11% 
in the placebo group), somnolence (5/33, 15.15% vs 0/18, 
0% in the placebo group), and headache (4/33, 12.12% vs 
0/18, 0% in the placebo group).
Uncontrolled studies
In a retrospective 8-week open-label study34 in 20 elderly 
patients (mean 64 years, range 49–89) with complex partial 
seizures under ZNS as add-on therapy, three patients discon-
tinued ZNS (one for skin rash, one for visual hallucinations, 
and one for drowsiness). In addition, among 16 responder 
patients, five reported mild gastrointestinal upset and sleepi-
ness without leading to ZNS discontinuation.
In a further retrospective open-label study35 conducted 
in 60 elderly epileptic patients treated with ZNS (as mono-
therapy or add-on treatment), six patients (10%) discontinued 
ZNS, five due to unspecified adverse events (8.3%). The most 
frequent TEAEs were gastrointestinal upset, skin rash, and 
mild somnolence (2/60, 3.3% each) followed by anorexia, 
vision changes, headache, and lightheadedness (1/60, 1.7% 
each). In a retrospective analysis36 comparing effectiveness of 
ten AEDs in old adults, the most frequent TEAEs leading to 
treatment discontinuation and/or to the dose change in more 
than 2% of patients in the ZNS-treated patients (n=30) were 
as follows: cognitive and gastrointestinal (10%–19.9%); 
allergies, dizziness, and headache (5%–9.9%); drowsiness, 
psychiatric effects, sleep difficulty, and vision (2%–4.9%).
Discussion
Seizures and epilepsy represent the third most frequent neu-
rological disorder in the elderly. The incidence of epilepsy 
increases exponentially in people aged $65 years. The treat-
ment of epilepsy in elderly patients can be challenging due 
to the fact that toxicity may be associated with concomitant 
treatments or medical conditions such as stroke, Alzheimer’s, 
or Parkinson’s disease. Several aspects may become complex 
treatment choices in elderly patients with epilepsy; therefore, 
physicians should pay attention in the management of sei-
zures and epilepsy in this age-specific group. AEDs choice 
and dosing should consider the age-related physiological 
changes, comorbidities, concomitant treatment, and drug 
interactions. Although the primary goals of epilepsy therapy 
are similar in all ages, the abovementioned concerns become 
noteworthy issues managing epilepsy in older people. Thus, 
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drug selection needs to take into account not only efficacy but 
also tolerability and safety issues. Desirable characteristics 
of an AED for the management of epilepsy in aging are as 
follows: i) favorable safety profile; ii) absence of drug–drug 
interactions (concomitant treatment with AEDs and other 
medications); iii) weak influence on cognitive function; and 
iv) long half-life in order to allow one or two daily intakes.38 
Older patients with new onset epilepsy are often started 
on first-generation AEDs despite their poor tolerability. 
However, the second-generation AEDs are characterized 
by a better pharmacokinetic and tolerability profile and are 
best suited for the management of epilepsy in the elderly.24 
The pharmacokinetic profile of ZNS (long half-life, mild 
drug–drug interactions, and no induction or inhibition of the 
hepatic microsomal enzymes) can be considered favorable 
for the management of epilepsy in the elderly.15,29 This review 
showed several concerns. First, to offer the most recent esti-
mation of the topic, we embraced abstracts from congress 
proceedings. Often, abstracts may not include significant 
aspects and are not subject to peer-reviewing processes. In 
addition, we derived data from the abstract itself and not 
from the posters. Therefore, some additional data regarding 
safety and efficacy of ZNS in elderly patients with epilepsy 
may have been missed by this approach. In addition, we can-
not obtain comparisons regarding the frequency of adverse 
events between add-on and monotherapy studies. Although 
the few data obtained from the literature may be encourag-
ing, we are far from obtaining generalizations regarding ZNS 
as AED in elderly population. Efficacy data from a single 
controlled study on efficacy of ZNS in elderly patients32 do 
not allow any conclusion because the data analysis is ongo-
ing, and the sample size seems too small. ZNS is often well 
tolerated, but some authors suggested that its use may be 
limited by somnolence, psychiatric, and cognitive adverse 
effects.37,39 Psychiatric adverse events include depression, 
irritability, aggressive behavior, and psychosis, whereas 
cognitive adverse events comprise language impairment, 
cognitive slowing, memory impairment, and reduced mental 
concentration in a manner similar to topiramate.39,40 Although 
specific findings regarding psychiatric and cognitive profile 
of ZNS in older patients are lacking, cognitive and psychiatric 
adverse effects may be common during ZNS treatment, but 
they are related to specific risk factors (ie, past psychiat-
ric history, symptomatic generalized epilepsy, number of 
concomitant AEDs, and ZNS serum levels)39 with a low 
discontinuation rate in selected patients.41 The favorable 
ZNS pharmacokinetic profile, the lack of interaction, may 
represent the strength of the choice of ZNS in the elderly. 
Although efficacy data are lacking, safety and tolerability 
of ZNS were recently evaluated in a pooled data analysis 
of five double-blind and two open-label studies conducted 
by Trinka et al4 in patients aged $65 years. In this analysis 
as well as in other uncontrolled studies, it has been reported 
that elderly patients treated with ZNS did not present more 
adverse events than the non-elderly. However, the relatively 
high frequency of cognitive and sedative adverse effects (ie, 
somnolence, headache, and dizziness) should be taken into 
account when ZNS is used in elderly patients.13,37 On the other 
hand, ZNS is effective in several disorders (ie, migraine, 
Parkinson’s disease, obesity, and sleep disorders) that may 
affect elderly subjects.14,42–44 Therefore, ZNS may represent 
a useful option for the obese patients due to weight loss, for 
migraine, for patients affected by Parkinson’s disease, and 
for sleep complaints. Recently, Eskandari et al42 showed a 
significant decrease of sleep apnea in a randomized placebo-
controlled design independent of weight loss and probably 
due to carbonic anhydrase inhibition. On the contrary, treat-
ment with ZNS should be avoided in patients with multiple 
or severe prior allergy/rash and renal stones. In a survey of 
experts for the treatment of symptomatic focal epilepsy in the 
elderly conducted in 2005, ZNS was recognized as first-line 
treatment by 39% and as second line by 56%.45 Lamotrigine, 
levetiracetam, gabapentin, oxcarbazepine, and carbam-
azepine were considered as first-line AEDs by 98%, 95%, 
71%, 61%, and 59%.45
Conclusion
Based on our review, we conclude that, to date, there is no 
satisfactory evidence on the efficacy and tolerability of ZNS 
in the treatment of elderly patients with epilepsy, although 
the data from a limited number of studies are encouraging. 
Large controlled prospective studies are needed to establish 
the real role of newer generation AEDs, such as ZNS, in the 
management of epilepsy in the elderly.
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